Search Within

David Hyman

  1. "Alexander Drilon"
Formats
  1. Meeting Abstract (45)
  2. Journal Article (32)
  3. Research Letter (1)
Groups
  1. Department of Medicine (78)
  2. Early Drug Development Service (78)
  3. Solid Tumor Oncology Division (78)
  4. Thoracic Oncology (78)
  5. Department of Pathology and Laboratory Medicine (42)
  6. GSK Faculty (41)

More Groups

People
  1. Alexander Drilon (78)
  2. Marc Ladanyi (29)
  3. Jaclyn Hechtman (24)
  4. Alison Schram (23)
  5. Ryma Benayed (22)
  6. Michael Berger (20)

More People

Years
  1. 2022 (1)
  2. 2021 (3)
  3. 2020 (16)
  4. 2019 (24)
  5. 2018 (12)
  6. 2017 (8)

More Years

Publications
  1. Journal of Clinical Oncology (15)
  2. Annals of Oncology (11)
  3. Cancer Research (8)
  4. JCO Precision Oncology (5)
  5. Journal of Thoracic Oncology (5)
  6. Cancer Discovery (4)

More Publications

Publishers
  1. American Society of Clinical Oncology (20)
  2. American Association for Cancer Research (17)
  3. Oxford University Press (12)
  4. Elsevier Inc. (6)
  5. Nature Publishing Group (6)
  6. Nature Research (3)

More Publishers

Results (78)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Repotrectinib (TPX-0005) is a next-generation ROS1/TRK/ALK inhibitor that potently inhibits ROS1/TRK/ALK solvent-front mutations
    Journal Article

    Drilon, A.; Ou, S. H. I.; Cho, B. C.; Kim, D. W.; Lee, J.; Lin, J. J.; Zhu, V. W.; Ahn, M. J.; Camidge, D. R.; Nguyen, J.; more...
    Cancer Discovery (2018)

    Fulltext@MSK | Save
  • Learning all that we can from MyPathway
    Journal Article

    Tao, J. J.; Schram, A. M.; Harding, J. J.; Drilon, A.; Hyman, D. M.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • NTRK fusions define a novel uterine sarcoma subtype with features of fibrosarcoma
    Journal Article

    Chiang, S.; Cotzia, P.; Hyman, D. M.; Drilon, A.; Tap, W. D.; Zhang, L.; Hechtman, J. F.; Frosina, D.; Jungbluth, A. A.; Murali, R.; more...
    American Journal of Surgical Pathology (2018)

    Fulltext@MSK | Save
  • NTRK fusions define a novel uterine sarcoma subtype with features of fibrosarcoma
    Meeting Abstract

    Chiang, S.; Cotzia, P.; Hyman, D.; Drilon, A.; Hechtman, J.; Jungbluth, A.; Murali, R.; Soslow, R.; Oliva, E.; Benayed, R.; more...
    Modern Pathology (2018)

    Fulltext@MSK | Save
  • Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children
    Journal Article

    Drilon, A.; Laetsch, T. W.; Kummar, S.; DuBois, S. G.; Lassen, U. N.; Demetri, G. D.; Nathenson, M.; Doebele, R. C.; Farago, A. F.; Pappo, A. S.; more...
    New England Journal of Medicine (2018)

    Fulltext@MSK | Save
  • HER kinase inhibition in patients with HER2-and HER3-mutant cancers
    Journal Article

    Hyman, D. M.; Piha-Paul, S. A.; Won, H.; Rodon, J.; Saura, C.; Shapiro, G. I.; Juric, D.; Quinn, D. I.; Moreno, V.; Doger, B.; more...
    Nature (2018)

    Fulltext@MSK | Save
  • Successful targeted therapy of refractory pediatric ETV6-NTRK3 fusion-positive secretory breast carcinoma
    Journal Article

    Shukla, N.; Roberts, S. S.; Baki, M. O.; Mushtaq, Q.; Goss, P. E.; Park, B. H.; Gundem, G.; Tian, K.; Geiger, H.; Redfield, K.; more...
    JCO Precision Oncology (2017)

    Fulltext@MSK | Save
  • The efficacy of larotrectinib (LOXO-101), a selective tropomyosin receptor kinase (TRK) inhibitor, in adult and pediatric TRK fusion cancers
    Meeting Abstract

    Hyman, D. M.; Laetsch, T. W.; Kummar, S.; DuBois, S. G.; Farago, A. F.; Pappo, A. S.; Demetri, G. D.; El-Deiry, W. S.; Lassen, U. N.; Dowlati, A.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel
    Journal Article

    Smyth, L. M.; Monson, K. R.; Jhaveri, K.; Drilon, A.; Li, B. T.; Abida, W.; Iyer, G.; Gerecitano, J. F.; Gounder, M.; Harding, J. J.; more...
    Investigational New Drugs (2017)

    Fulltext@MSK | Save
  • Pan-TRK immunohistochemistry is an efficient and reliable screen for the detection of NTRK fusions
    Journal Article

    Hechtman, J. F.; Benayed, R.; Hyman, D. M.; Drilon, A.; Zehir, A.; Frosina, D.; Arcila, M. E.; Dogan, S.; Klimstra, D. S.; Ladanyi, M.; more...
    American Journal of Surgical Pathology (2017)

    Fulltext@MSK | Save